The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Open accessAbstract
Oral daily (2.5 mg) and intermittent ibandronate (between-dose interval of >2 months), delivering a similar cumulative exposure, were evaluated in 2946 osteoporotic women with prevalent vertebral fracture. Significant reduction in incident vertebral fracture risk by 62% and 50%, respectively, was shown after 3 years. This is the first study to prospectively show antifracture efficacy for the intermittent administration of a bisphosphonate. Introduction: Bisphosphonates are important therapeutics in postmenopausal osteoporosis. However, they are currently associated with stringent dosing instructions that may impair patient compliance and hence therapeutic efficacy. Less frequent, intermittent administration may help to overcome these deficiencies. This study assessed the efficacy and safety of oral ibandronate administered either daily or intermittently with a dose-free interval of >2 months. Materials and Methods: This randomized, double-blind, placebo-controlled, parallel-group study enrolled 2946 postmenopausal women with a BMD T score ≤ −2.0 at the lumbar spine in at least one vertebra (L1-L4) and one to four prevalent vertebral fractures (T4-L4). Patients received placebo or oral ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months). Results and Conclusions: After 3 years, the rate of new vertebral fractures was significantly reduced in patients receiving oral daily (4.7%) and intermittent ibandronate (4.9%), relative to placebo (9.6%). Thus, daily and intermittent oral ibandronate significantly reduced the risk of new morphometric vertebral fractures by 62% (p = 0.0001) and 50% (p = 0.0006), respectively, versus placebo. Both treatment groups also produced a statistically significant relative risk reduction in clinical vertebral fractures (49% and 48% for daily and intermittent ibandronate, respectively). Significant and progressive increases in lumbar spine (6.5%, 5.7%, and 1.3% for daily ibandronate, intermittent ibandronate, and placebo, respectively, at 3 years) and hip BMD, normalization of bone turnover, and significantly less height loss than in the placebo group were also observed for both ibandronate regimens. The overall population was at low risk for osteoporotic fractures. Consequently, the incidence of nonvertebral fractures was similar between the ibandronate and placebo groups after 3 years (9.1%, 8.9%, and 8.2% in the daily, intermittent, and placebo groups, respectively; difference between arms not significant). However, findings from a posthoc analysis showed that the daily regimen reduces the risk of nonvertebral fractures (69%; p = 0.012) in a higher-risk subgroup (femoral neck BMD T score < −3.0). In addition, oral ibandronate was well tolerated. Oral ibandronate, whether administered daily or intermittently with an extended between-dose interval of >2 months, is highly effective in reducing the incidence of osteoporotic fractures in postmenopausal women. This is the first time that significant fracture efficacy has been prospectively shown with an intermittently administered bisphosphonate in the overall study population of a randomized, controlled clinical trial. Thus, oral ibandronate holds promise as an effective and convenient alternative to current bisphosphonate therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276
Self-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Noninvasive assessment of bone mineral and structure: State of the art
Genant, H. K., Engelke, K., Fuerst, T. P., Glüer, C., Grampp, S., Harris, S. T., Jergas, M. D., Lang, T., Lü, Y., Majumdar, S., et al. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110602 · Cited by 948
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P. D., Woodson, G. C., Yanover, M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 947
Self-citationStorm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sørensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 926
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A. G., Stephenson, W. P., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 763
Garnero, P., Shih, W. J., Gineyts, É., Karpf, D. B., & Delmas, P. D. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989477 · Cited by 706
Self-citationPols, H. A. P., Felsenberg, D., Hanley, D. A., Stepan, J. J., Muñoz‐Torres, M., Wilkin, T. J., Ge, Q.-S., Galich, A. M., Vandormael, K., Yates, A. J. P., et al. (1999) · Osteoporosis International · doi:10.1007/pl00004171 · Cited by 586
Self-citationJones, G., Nguyen, T. V., Sambrook, P. N., Kelly, P. J., Gilbert, C., & Eisman, J. A. (1994) · Osteoporosis International · doi:10.1007/bf01623352 · Cited by 484
Immunoassay for quantifying type I collagen degradation products in urine evaluated
Bonde, M., Qvist, P., Fledelius, C., Riis, B. J., & Christiansen, C. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.11.2022 · Cited by 323
Self-citationDelmas, P. D., Balena, R., Confravreux, E., Hardouin, C., Hardy, P., & Bremond, A. G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.955 · Cited by 278
Self-citationBisphosphonates: Pharmacology, Mechanisms of Action and Clinical Uses
Russell, R. G. G., Croucher, P. I., & Rogers, M. J. (1999) · Osteoporosis International · doi:10.1007/pl00004164 · Cited by 241
Report assessing vertebral fractures
Steven, R. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100403 · Cited by 241
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., & Fleisch, H. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060915 · Cited by 239
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., WASNICH, E. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P. D., Woodson, G. C., Yanover, M., et al. (1991) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199101000-00023 · Cited by 190
Self-citationThe economic and human costs ofosteoporotic fracture
Barrett-Connor, E. L. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(05)80037-3 · Cited by 189
Three Monthly Intravenous Injections of Ibandronate in the Treatment of Postmenopausal Osteoporosis
Thiébaud, D., Burckhardt, P., Kriegbaum, H., Huss, H., Mulder, H., Juttmann, J. R., & Schöter, K.-H. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00249-0 · Cited by 186
Self-citationMeasurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies
Rosenquist, C., Qvist, P., Bjarnason, N. H., & Christiansen, C. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.10.1439 · Cited by 177
Self-citationRecker, R. R., Stakkestad, J. A., Chesnut, C. H., Christiansen, C., Skag, A., Høiseth, A. D., Ettinger, M. P., Mahoney, P., Schimmer, R. C., & Delmas, P. D. (2004) · Bone · doi:10.1016/j.bone.2004.01.008 · Cited by 172
Self-citationClinical pharmacology of alendronate sodium
Gertz, B. J., Holland, S. D., Kline, W. F., Matuszewski, B. K., & Porras, A. G. (1993) · Osteoporosis International · doi:10.1007/bf01623002 · Cited by 163
Ravn, P., Clemmesen, B., Riis, B. J., & Christiansen, C. (1996) · Bone · doi:10.1016/s8756-3282(96)00229-3 · Cited by 150
Self-citationEttinger, B. B., Pressman, A. R., & Schein, J. R. (1998) · PubMed · Cited by 133
Rosalki, S. B., Foo, A. Y., Burlina, A., Prellwitz, W., Stieber, P., Neumeier, D., Klein, G., Poppe, W., & Bodenmüller, H. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.4.648 · Cited by 130
Thiébaud, D., Burckhardt, P., Melchior, J., Eckert, P., Jacquet, A. F., Schnyder, P., & Gobelet, C. (1994) · Osteoporosis International · doi:10.1007/bf01623227 · Cited by 112
Vertebral Fracture in Osteoporosis
Suk, S. I., Lee, C., Kang, H. S., Lee, J. H., 민학진, Cha, S. H., & Chung, Y. J. (1993) · The Journal of the Korean Orthopaedic Association · doi:10.4055/jkoa.1993.28.3.980 · Cited by 110
Smith, S. Y., Recker, R. R., Hannan, M. T., Müller, R., & Bauss, F. (2003) · Bone · doi:10.1016/s8756-3282(02)00923-7 · Cited by 104
Self-citationRiis, B. J., Ise, J., Stein, T. V., Bagger, Y. Z., & Christiansen, C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.10.1871 · Cited by 100
Self-citationEfficacy and safety of ibandronate given by intravenous injection once every 3 months
Adámi, S., Felsenberg, D., Christiansen, C., Robinson, J., Lorenc, R. S., Mahoney, P., Coutant, K., Schimmer, R. C., & Delmas, P. D. (2004) · Bone · doi:10.1016/j.bone.2004.01.007 · Cited by 99
Self-citationWeekly administration of alendronate: Rationale and plan for clinical assessment
Bone, H. G., Adámi, S., Rizzoli, R., Favus, M. J., Ross, P. D., Santora, A. C., Prahalada, S. R., Daifotis, A. G., Orloff, J. J., & Yates, J. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)87974-6 · Cited by 97
Monier‐Faugere, M., Geng, Z., Paschalis, E. P., Qi, Q., Arnala, I., Bauss, F., Boskey, A. L., & Malluche, H. H. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1768 · Cited by 95
Bauss, F., Lalla, S., Endele, R., & Hothorn, L. A. (2002) · PubMed · Cited by 86
Passeri, M., Baroni, M. C., Pedrazzoni, M., Pioli, G., Barbagallo, M., Costi, D., Biondi, M., Girasole, G., Arlunno, B., & Palummeri, E. (1991) · Bone and Mineral · doi:10.1016/0169-6009(91)90129-n · Cited by 75
Filipponi, P., Pedetti, M., FEDELI, L., Cini, L., Palumbo, R., Boldrini, S., Massoni, C., & Cristallini, S. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100505 · Cited by 72
Schimmer, R. C., & Bauss, F. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90005-1 · Cited by 51
Self-citationUse of bisphosphonates in the management of postmenopausal osteoporosis
Papapoulos, S. E. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05767.x · Cited by 45
Bisphosphonates in the Management of Postmenopausal Osteoporosis
Papapoulos, S. E. (2001) · Elsevier eBooks · doi:10.1016/b978-012470862-4/50073-8 · Cited by 19
HP4 THE IMPACT OF ADHERENCE TO OSTEOPOROSIS THERAPY ON FRACTURE RATES IN ACTUAL PRACTICE
Jaime, J., Huybrechts, K. F., Ishak, K. J., & Naujoks, C. (2002) · Value in Health · doi:10.1016/s1098-3015(10)60836-4 · Cited by 4
Flagged first, then by citations
Research works printed but not linked: 4
- Melton, 1991, Long-term fracture risk prediction with bone mineral measurements made at various skeletal sites, J Bone Miner Res, 6, S136
- Kendler, 2002, Patient preference of once weekly or daily administration of alendronate (Fosamax) for osteoporosis: a randomized cross-over study, Osteoporos Int, 13, S32
- Palmisano, 2002, Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis, Osteoporos Int, 13, S36
- Kiel, 1995, Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures, J Bone Miner Res, 10, 518
Cited by
Sorted by citations
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citationOnce-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C. C., Rizzoli, R., & Reginster, J. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,993
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Metadata
- Authors
- Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., Delmas, P. D., & (BONE), F. T. O. I. O. V. F. T. I. N. A. A. E.
- Affiliations
- University of Washington (US)
- Center for Clinical Trials, Bergen, Norway
- Center for Clinical & Basic Research (DK)
- Creighton University (US)
- CECOR AS, Haugesund, Norway
- Oslo Department, Sentrum Røntgen Institut AS, Oslo, Norway
- Universitatsklinikum Benjamin Franklin, Berlin, Germany
- Leverkusen, Germany
- Roche (United Kingdom) (GB)
- F. Hoffmann-La Roche AG (CH)
- Lyon 1 Université (FR)
- Corresponding author
- Chesnut, Charles H
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-01
- Volume
- 19
- Issue
- 8
- Pages
- 1241-1249
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2099054178
- Cited by
- 1,229
- References
- 42
- Citations by year
- 2026: 14 · 2025: 38 · 2024: 20 · 2023: 42 · 2022: 31 · 2021: 37 · 2020: 35 · 2019: 32 · 2018: 32 · 2017: 31 · 2016: 43 · 2015: 45 · 2014: 45 · 2013: 63 · 2012: 62
- FWCI
- 85.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- ibandronate, intermittent dosing, bisphosphonates, postmenopausal osteoporosis, vertebral fractures, fracture risk reduction, bone mineral density, bone turnover, height loss, drug safety, medication adherence, lumbar spine, hip bone density, antifracture efficacy, treatment discontinuation, adverse events
- MeSH terms
- Ibandronic Acid, Aged, Body Height, Bone and Bones, Diphosphonates, Double-Blind Method, Female, Femur, Humans, Lumbar Vertebrae, Middle Aged, Pelvic Bones, Prospective Studies, Risk Factors, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome, Patient Selection, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
